Abstract
OBJECTIVE: To investigate the effects of a near-physiological peripheral glucagon-like peptide-1 (GLP-1) infusion, during and after a breakfast of fixed energy content, on resting energy expenditure, substrate oxidation and metabolism and the desire to eat specific types of food in humans.
DESIGN: A placebo-controlled, randomized, blinded, cross-over study. Infusion (GLP-1, 50 pmol/kg×h or saline) was started simultaneously with initiation of the test meals.
SUBJECTS: 20 healthy, normal weight (body mass index 20.3–25.7 kg/m2) men of 20–31 y of age.
MEASUREMENTS: Energy expenditure and substrate oxidations were measured before and for 4 h after standard breakfast (20% of calculated daily energy requirements, 50% of energy from carbohydrates, 37% of energy from fat and 13% of energy from protein) using a ventilated hood system. Visual analogue scales were used throughout the experiment to assess the desire to eat specific types of food and the palatability of the test meals. Blood was sampled throughout the day for analysis of plasma hormone and substrate concentrations.
RESULTS: Diet-induced thermogenesis (DIT) was lower (47%) on the GLP-1 infusion than on the saline infusion (P<0.0001). This was due to a lower carbohydrate oxidation (P<0.01). No differences in fat oxidation or total 4 h protein oxidation were observed. All hormone and substrate profiles except non-esterified fatty acids (NEFA) and cholecystokinin (CCK) were significantly suppressed (GLP-2 completely suppressed) during the GLP-1 infusion, whereas profiles of NEFA and CCK differed in time course during the two treatments (treatment × time effect), P<0.0001). GLP-1 infusion also suppressed the desire to eat all food types following the breakfast (treatment effect: P<0.05).
CONCLUSION: Peripheral GLP-1 decreased DIT and carbohydrate oxidation, probably secondary to a delayed absorption of nutrients, since substrate and hormone concentrations in plasma were suppressed during GLP-1 infusion. Endogenous secretion of GLP-1 and GLP-2 was completely suppressed by GLP-1 infusion. Finally, the desire to eat any type of food was decreased by exogenous administrated GLP-1.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Varndell IM, Bishop AE, Sikri KL, Uttenthal LO, Bloom SR, Polak JM . Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry J Histochem Cytochem 1985 33 (10): 1080–1086.
Eissele R, Göke R, Willemer S, Harthus H-P, Vermer H, Arnold R, Göke B . Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man Eur J Clin Invest 1992 22: 283–291.
Kreymann B, Williams G, Ghatei MA, Bloom SR . Glucagon-like peptide-1 7–36: a physiological incretin in man Lancet 1987 ii: 1300–1303.
Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V . Glucagon-like peptide-1 (7–36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns J Endocrinol 1993 138: 159–166.
Qualmann C, Nauck MA, Holst JJ, Ørskov C, Creutzfeldt W . Glucagon-like peptide-1 (7–36 amide) secretion in response to luminal sucrose from the upper and lower gut Scand J Gastroenterol 1995 30: 892–896.
Ørskov C, Wettergren A, Holst JJ . Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day Scand J Gastroenterol 1996 31: 665–670.
Holst JJ, Ørskov C, Nielsen OV, Schwartz TW . Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut FEBS Lett 1987 211 (2): 169–174.
Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W . Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1 (7–36) amide infused at near-physiological insulinotropic hormone and glucose concentrations J Clin Endocrinol Metab 1993 76 (4): 912–917.
Hvidberg A, Nielsen MT, Hilsted J, Ørskov C, Holst JJ . Effect of glucagon-like peptide-1 (proglucagon 78–107 amide) on hepatic glucose production in healthy man Metabolism 1994 43: 104–108.
Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W . Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients Diabetologia 1993 36: 741–744.
Holst JJ, Nauck MA, Deacon CF, Ørskov C . Potential of GLP-1 in diabetes management. In Lefebvre PJ (ed.) Glucagon III. Handbook of experimental pharmacology, Vol 123. Springer: Berlin, 1996, pp 311–326.
O'Halloran DJ, Nikou GC, Kreymann B, Ghatei MA, Bloom SR . Glucagon-like peptide-1 (7–36)-NH2: a physiological inhibitor of gastric acid secretion in man J Endocrinol 1990 126: 169–173.
Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ . Truncated GLP-1 (proglucagon 78–107 amide) inhibits gastric and pancreatic functions in man Dig Dis Sci 1993 38 (4): 665–673.
Wettergren A, Petersen H, Ørskov C, Christiansen J, Sheikh SP, Holst JJ . Glucagon-like peptide-1 7–36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man Scand J Gastroenterol 1994 29: 501–505.
Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzel R, Schmiegel WH . Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans Am J Physiol 1997 273 (Endocrinol Metab 36): E981–E988.
Schick RR, vorm Walde T, Zimmermann JP, Schusdziarra V, Classen M . Glucagon-like peptide 1—a novel brain peptide involved in feeding regulation. In: Ditschuneit H, Gries FA, Hauner H, Schusdziarra V, Wechsler JG (eds). Obesity in Europe 1993; Chap 53, pp 363–367. John Libbey & Company Ltd. 1994.
Turton MD, O'Shea D, Gunn I, Beak SA, Edwards MB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JPH, Smith DM, Ghatei MA, Herbert J, Bloom SR . A role for glucagon-like peptide-1 in the central regulation of feeding Nature 1996 379: 69–72.
Tang-Christensen M, Larsen PJ, Göke R, Fink-Jensen A, Jessop DA, Møller M Sheikh SP . Central administration of GLP-1 (7–36) amide inhibits food and water intake in rats Am J Physiol 1996 271: (Regulatory Integrative Comp Physiol 40) R848–R856.
Flint A, Raben A, Astrup A, Holst JJ . Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998 101 (3): 515–520.
Näslund E, Gutniak M, Skogar S, Rössner S, Hellström PM . Glucagon-like peptide-1 (GLP-1) increases the period of postprandial satiety and slows gastric emptying in obese humans Am J Clin Nutr 1998 68: 525–530.
Gutzwiller JP, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C . Glucagon-like peptide-1: a potent regulator of food intake in humans Gut 1999 44: 81–86.
Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rössner S, Hellström PM . Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men Int J Obes 1999 23: 304–311.
Holst JJ, Schwartz TM, Lovgreen NA, Pedersen O, Beck-Nielsen H . Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity Int J Obes 1983 7: 529–538.
Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V . Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 1996 38: 916–919.
Näslund E, Grybäck P, Backman L, Jacobsson H, Holst JJ, Theodorsson E, Hellström PM . Distal small bowel hormones: correlation with fasting antro-duodenal motility and gastric emptying Dig Dis Sci 1998 43: 945–952.
Division of Noncommunicable Diseases/World Health Organization/Programme of Nutrition Family and Reproductive Health . Obesity—preventing and managing the global epidemic. Report of a WHO Consultation on Obesity, WHO/NUT/NCD/98.1. World Health Organization: Geneva, 1998.
Hwa JJ, Ghibaudi L, Williams P, Witten MB, Tedesco R, Strader CD . Differential effects of intracerebroventricular glucagon-like peptide-1 on feeding and energy expenditure regulation Peptides 1998 19 (5): 869–875.
Shalev A, Holst JJ, Keller U . Effects of glucagon-like peptide 1 (7–36 amide) on whole-body protein metabolism in healthy man Eur J Clin Invest 1997 27 (1): 10–16.
Food and Agriculture Organization/World Health Organization/United Nations University . Energy and protein requirements. Report of a joint FAO/WHO/UNV Expert Consultation, Technical Report Series 74. World Health Organization: Geneva, 1985.
Costill DL . Carbohydrates for exercise: dietary demands for optimal performance Int J Sports Med 1988 9: 1–18.
Raben A, Mygind E, Saltin B, Astrup A . Lower activity of oxidative key enzymes and smaller fiber areas in skeletal muscle of post-obese women Am J Physiol: Endocrinol Metab 1998 275: E487–E494.
Raben A, Tagliabue A, Astrup A . The reproducibility of subjective appetite scores Br J Nutr 1995 73: 517–530.
Fellows IW, Macdonald IA . An automated method for the measurement of oxygen consumption and carbon dioxide excretion in man Clin Phys Physiol Meas 1985 6 (4):: 349–355.
Elia M, Livesey G . Energy expenditure and fuel selection in biological systems: the theory and practice of calculations based on indirect calorimetry and tracer methods. In Simopoulus AP (ed). Metabolic control of eating, energy expenditure and the bioenergetics of obesity. World Review on Nutrition and Diet. Karger: Basel, 1992, Vol 70, pp 68–131.
Wahlefeld AW . Triglycerides. Determination after enzymatic hydrolysis. In Bergmayer HU (ed). Methods of enzymatic analysis, 2nd edn. Academic Press: New York, 1974.
Deeg R, Kraemer W, Ziegenhorr J . Kinetic determination of serum glucose by use of the hexokinase/glucose-6-phosphate dehydrogenase method J Clin Chem Clin Biochem 1980 18: 49–52.
Noll F . L-(+)-Lactate. Determination with LDH, GPT and NAD. In Bergmayer HU (ed). Methods of enzymatic analysis, 2nd edn. Academic Press: New York, 1974.
Albano JDM, Ekins RP, Maritz G, Turner RC . A sensitive precise radioimmunoassay of serum insulin relying on charcoal separation of bound and free hormone moieties Acta Endocrinol 1972 70: 487–509.
Ørskov C, Rabenjøj A, Wettergren A, Kofod H, Holst JJ . Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans Diabetes 1994 43: 535–539.
Hartmann B, Johnsen AH, Ørskov C, Holst JJ . Structure, analysis and secretion of human glucagon-like peptide-2 (GLP-2) (abstract) Diabetes 1996 45 (Suppl 2): 300A.
Krarup T, Madsblad S, Moody AJ, Regeur L, Faber OK, Holst JJ, Sestoft L . Diminished immunoreactive gastric inhibitory polypeptide response to a meal newly diagnosed type 1 (insulin-dependent) diabetes J Clin Endocrinol Metab 1983 56 (6): 1306–1312.
Rehfeld JF . Accurate measurement of cholecystokinin in plasma Clin Chem 1998 44: 991–1001.
Kirsten WJ, Hesselius GU . Rapid, automatic, high capacity Dumas determination of nitrogen Microchem J 1983 28: 529–547.
Raben A, Tagliabue A, Christensen NJ, Madsen J, Holst JJ, Astrup A . Resistant starch: the effect on postprandial glycemia, hormonal response, and satiety Am J Clin Nutr 1994 60: 544–551.
Raben A, Andersen HB, Christensen NJ, Madsen J, Holst JJ, Astrup A . Evidence for an abnormal postprandial response to a high fat meal in women predisposed to obesity Am J Physiol 1994 267: E549–E559.
Frayn KN . Studies of human adipose tissue in vivo. In Kinney JM, Tucker HN (eds). Energy Metabolism: Tissue Determinants and Cellular Corollaries. Raven Press: New York, 1992, pp 267–295.
Barragán JM, Rodriguez RE, Blázquez E . Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7–36) amide in rats Am J Physiol 1994 266 (Endocrinol Metab 29): E459–E466.
Holst JJ . Enteroglucagon A Rev Physiol 1997 59: 257–271.
Nauck M . Therapetuic potential of glucagon-like peptide 1 in type 2 diabetes Diabetic Med 1996 13: S39–S43.
Read N, French S, Cunningham K . The role of the gut in regulating food intake in man Nutr Rev 1994 52: 1–10.
Ørskov C, Holst JJ, Knuhtsen S, Baldissera FGA, Plulsen Ss, Nielsen OV . Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from the pig small intestine, but not pancreas Endocrinology 1986 119: 1467–1475.
Nauck MA, Siemsglüss, Ørskov C, Holst JJ . Release of glucagon-like peptide 1 (GLP-1) [7–36 amide] in response to glucose after upper and lower intestinal resection Z Gastroenterol 1996 34: 159–166.
Ritzel R, Ørskov C, Holst JJ, Nauck MA . Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 (7–36 amide) after subcutaneous injection in healthy volunteers. Dose–response-relationships Diabetologia 1995 38:: 720–725.
Larsen J, Jallad N, Damsbo P . One-week continuous infusion of GLP-1 (7–37) improves glycemic control in NIDDM Diabetes 1996 45 (Suppl 2): 233A (abstract).
Acknowledgements
The authors gratefully thank Inge Timmermann, Bente Knap, Charlotte Kostecki, Karina G Larsen, Lone K Larsen, John Lind, Tina Cutherbertson, Trine Jessen and Lene Albaek for expert technical assistance. This study was supported by the Danish Research and Development Program for Food Technology 1990–1994 and the Danish Medical Research Council. JJ Holst was supported by the Danish Biotechnology Program.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Flint, A., Raben, A., Rehfeld, J. et al. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes 24, 288–298 (2000). https://doi.org/10.1038/sj.ijo.0801126
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0801126
Keywords
This article is cited by
-
Gut microbiota in human metabolic health and disease
Nature Reviews Microbiology (2021)
-
The evolving view of thermogenic adipocytes — ontogeny, niche and function
Nature Reviews Endocrinology (2021)
-
Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome
Current Diabetes Reports (2020)
-
Does endogenous GLP-1 affect resting energy expenditure and fuel selection in overweight and obese adults?
Journal of Endocrinological Investigation (2018)
-
Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system
International Journal of Obesity (2017)